Cited 3 times in
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.